Efficacy and safety of brigatinib in the first-line treatment of
ALK-positive non-small cell lung cancer (NSCLC).
PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY
We invite you to participate in a multicenter observational study titled "Efficacy and safety of brigatinib in the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Prospective multicenter observational study."
To start the study, it is necessary to conclude an online agreement, so please register and follow the instructions appearing on the computer screen.
After successful registration and electronic signing of the agreement, please log in using the data obtained during the account setup process.
BioStat monitors the smooth running
of the study and data analysis.
BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
tel: +48 530 714 118
email: [email protected]
Takeda Pharma sp. z o.o.
Prosta 68, 00-838 Warsaw
tel: + 48 22 608 13 00/01
fax: + 48 22 608 13 03
Please log in using the data received after signing the online agreement.
Please fill out the registration form and join the study.